Jasper Therapeutics, Inc.
Clinical trials sponsored by Jasper Therapeutics, Inc., explained in plain language.
Biotech company developing therapies for blood disorders and cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New drug shows promise for Long-Term control of chronic hives
Disease control Stopped earlyThis study is testing the long-term safety and effectiveness of a drug called briquilimab for people with chronic hives. It includes 67 participants who have already completed a previous trial with the same drug. The goal is to see if briquilimab remains safe and helps control hi…
Phase 2 • Sponsor: Jasper Therapeutics, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Experimental asthma drug briquilimab fails to reach Late-Stage testing
Disease control Stopped earlyThis Phase 1 trial tested a single dose of briquilimab in 17 adults with mild-to-moderate allergic asthma to see if it was safe and could reduce asthma attacks triggered by allergens. The study was terminated early, meaning it did not continue as planned. The main goal was to che…
Phase 1 • Sponsor: Jasper Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 18:40 UTC
-
Experimental shot for Cold-Triggered hives tested, but trial stopped early
Symptom relief Stopped earlyThis early-stage trial tested a single dose of a drug called briquilimab in 27 adults with chronic hives caused by cold or friction that did not improve with standard allergy pills. The main goal was to check safety and see if the drug could reduce symptoms. However, the trial wa…
Phase 1/2 • Sponsor: Jasper Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC